“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.
ESMO Annual Congress
Shorts
0:30
Expert: Belzutifan plus lenvatinib advances outcomes in advanced ccRCC
14 days ago
by
Daniel Heng, MD, MPH, FRCPC
0:50
Srikala Sridhar, MD, discusses ALPACA study in penile cancer
a year ago
by
Srikala Sridhar, MD
0:51
Andrea Necchi, MD, discusses prognostic potential of utDNA and ctDNA in MIBC
a year ago
by
Andrea Necchi, MD
Latest Content
Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.
Advertisement
The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Survey: Service members and veterans with NMIBC report barriers to treatment access
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
Q&A: Ronald Anglade, MD, on genetic testing in male infertility
5